ONE MONTH to go until Beyond the Pink is out in the world!! Would love to see you on one of these book tour stops (and more to come). For info and registration links: drteplinsky.com/booktour.

It’s 10 days until publication day for 📗 Beyond The Pink and I am counting down with the 🔟 things I wish everyone knew about #breastcancer.

⭐️ How are #BreastCancer experts using #ctDNA in real-world practice? @MatthewKurianMD @mchayleh @drteplinsky @OncBrothers 🗣️ 🔹Detecting recurrence earlier 🔸Limitations 🔹Shared decision-making 🔸Future role of ctDNA in breast cancer care #bcsm 🎥👇 oncupdates.com/video-podcast…

FDA grants accelerated approval to Etcamah (camizestrant) + CDK4/6i (abemaciclib, palbociclib, ribociclib) for HR+/HER2- advanced BC upon ESR1 mutation detected during AI + CDK4/6i therapy, by FDA-authorized test. Pro: mPFS 16 vs 9.2 mo per label. In SERENA-6, final PFS2 25.7 vs 19.1 mo (HR 0.63) and 46% lower risk of deterioration in global health status/QOL. Con: Accelerated approval, OS immature, confirmatory trials required. Boxed warning for irregular heart rhythm with certain concomitant meds, plus bradycardia. First trial to intervene on molecular resistance in breast cancer before clinical PD. #bcsm

In a new NEJM Voices blog post, Don Dizon, MD, reflects on the profound shock of a colleague’s cancer diagnosis. Read “When Cancer Hits Home” and sign up for email alerts: nej.md/4i0fMK1

Rest in Power @ASCO Giant Dr Harold Paul Freeman 1933-2026 Your work outlining barriers to care and developing #patientNavigation has saved countless lives & was foundational to a generation of researchers like me. connection.asco.org/do/asco-…

It was lovely to speak with Eleonora Teplinsky (@drteplinsky) at #ASCO26 to discuss the importance of educating patients about the potential risks of using #AI for health information🖥️ Misinformation and "hallucination" by AI systems can create potential conflicts between clinician recommendations and impact patient outcomes 📉 Watch: ow.ly/rhCe50ZHLWU #Oncology @ASCO @ValleyHealthNJ

Not every patient needs an aromatase inhibitor. Eleonora Teplinsky, MD, FASCO, tells Sara Nunnery, MD, MSCI, why lowering recurrence risk in breast cancer must be individualized, not one-size-fits-all. 🎙️Watch the full episode of Breast Cancer Briefing on OncLive®: hubs.ly/Q04txPGV0 @SaraNunneryMD @drteplinsky #BreastCancerBriefing #RecurrenceRisk #PrecisionOncology #BreastCancer #OncLive

Dolly Parton is reported to have died from cancer. A reminder that cancer affects everyone. people.com/dolly-parton-died…

⭐️#ctDNA Testing Across #BreastCancer Subtypes ✅TNBC & HER2+→higher shedding ⏳Field evolving, subtype-specific guidance still maturing #bcsm #OncTwitter #HemOnc #MedEd @drteplinsky @MatthewKurianMD @mchayleh @OncBrothers 🎥 Full Video + Summary 👇 oncupdates.com/video-podcast…

ICYMI 💥: @FDA has granted fast track designation to BI-1808 plus pembrolizumab for ovarian cancer, supported by the ongoing phase 2a Keynote-D20 study. Read more here ➡️: onclive.com/view/fda-grants-… #ovca #oncology

I don’t think an expert in researching cancer or an expert in treating cancer would accept $50/hr so why should an expert in living with cancer?

Be proactive, not reactive. Eleonora Teplinsky, MD, FASCO, and Sara Nunnery, MD, MSCI, shares 3 questions every care team should ask about cardiovascular risk during breast cancer treatment. 🎧 Watch the full episode of Breast Cancer Briefing on OncLive®: hubs.li/Q04txtTW0 @SaraNunneryMD @drteplinsky #BreastCancerBriefing #CardioOncology #Cardiotoxicity #BreastCancer #OncLive

We squander too much of our free time feeling guilty that we’re not working. In 1 of every 7 moments of fun and relaxation, people feel bad that they're not being “productive”—robbing themselves of joy and rejuvenation. Leisure is not a bug. It’s a feature of a good life.

This study showed that about a third of women experience persistent fatigue after breast cancer treatment and they attributed it to depression and perceived stress rather than cardiometabolic factors. However, what about factors such as menopause, sleep quality/poor sleep, vasomotor symptoms, pain, neuropathy. I suspect they play a significant role. jamanetwork.com/journals/jam…

⭐️#ctDNA in #BreastCancer ✅Highest shedding in #TNBC ✅Helpful for response monitoring & high-risk surveillance 🤔Future:guide escalation/de-escalation (needs trial validation) #bcsm #OncTwitter @OncBrothers @MatthewKurianMD @drteplinsky @mchayleh 🎥👇 oncupdates.com/video-podcast…

On this episode of #BreastCancerBriefing, Drs Nunnery and Teplinsky discussed how to manage the adverse effects associated with endocrine therapy in hormone receptor–positive breast cancer. @SaraNunneryMD @drteplinsky @TNOncology @valleyhealthnj #bcsm #oncology Watch on our site or listen on your favorite podcast platform! onclive.com/view/breast-canc…

The amount of time you wear a bra does not increase your breast cancer risk. There is no evidence that wearing a bra for longer periods of time causes breast cancer. The fear mongering misinformation online has to stop.

It’s not enough to just require women get notification of dense breast tissue at time of #mammography.. if you actually want people to get supplemental screening you need to mandate that insurance PAY FOR IT. #bcsm #breastcancer jamanetwork.com/journals/jam… @JAMANetwork @JAMA_current

🎥 LIVE NOW: @drteplinsky is answering your questions and discussing her new book, "Beyond the Pink: Navigating Life, Health, and Breast Cancer." Tune in to hear her insights on navigating life during and after breast cancer, and get your copy with a signed bookplate. talkshop.live/watch/j_8_GqIm…